Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Control ; 31: 10732748241247170, 2024.
Article in English | MEDLINE | ID: mdl-38662732

ABSTRACT

Among the post-transcriptional modifications, m6A RNA methylation has gained significant research interest due to its critical role in regulating transcriptional expression. This modification affects RNA metabolism in several ways, including processing, nuclear export, translation, and decay, making it one of the most abundant transcriptional modifications and a crucial regulator of gene expression. The dysregulation of m6A RNA methylation-related proteins in many tumors has been shown to lead to the upregulation of oncoprotein expression, tumor initiation, proliferation, cancer cell progression, and metastasis.Although the impact of m6A RNA methylation on cancer cell growth and proliferation has been extensively studied, its role in DNA repair processes, which are crucial to the pathogenesis of various diseases, including cancer, remains unclear. However, recent studies have shown accumulating evidence that m6A RNA methylation significantly affects DNA repair processes and may play a role in cancer drug resistance. Therefore, a comprehensive literature review is necessary to explore the potential biological role of m6A-modified DNA repair processes in human cancer and cancer drug resistance.In conclusion, m6A RNA methylation is a crucial regulator of gene expression and a potential player in cancer development and drug resistance. Its dysregulation in many tumors leads to the upregulation of oncoprotein expression and tumor progression. Furthermore, the impact of m6A RNA methylation on DNA repair processes, although unclear, may play a crucial role in cancer drug resistance. Therefore, further studies are warranted to better understand the potential biological role of m6A-modified DNA repair processes in human cancer and cancer drug resistance.


Subject(s)
DNA Damage , DNA Repair , Drug Resistance, Neoplasm , Neoplasms , Humans , Neoplasms/genetics , Neoplasms/pathology , Neoplasms/therapy , Neoplasms/drug therapy , Drug Resistance, Neoplasm/genetics , Chemoradiotherapy/methods , Gene Expression Regulation, Neoplastic
2.
Cell Cycle ; 22(5): 506-526, 2023 03.
Article in English | MEDLINE | ID: mdl-36214587

ABSTRACT

Radiation-induced liver disease (RILD), also known as radiation hepatitis, is a serious side effect of radiotherapy (RT) for hepatocellular carcinoma. The therapeutic dose of RT can damage normal liver tissue, and the toxicity that accumulates around the irradiated liver tissue is related to numerous physiological and pathological processes. RILD may restrict treatment use or eventually deteriorate into liver fibrosis. However, the research on the mechanism of radiation-induced liver injury has seen little progress compared with that on radiation injury in other tissues, and no targeted clinical pharmacological treatment for RILD exists. The DNA damage response caused by ionizing radiation plays an important role in the pathogenesis and development of RILD. Therefore, in this review, we systematically summarize the molecular and cellular mechanisms involved in RILD. Such an analysis is essential for preventing the occurrence and development of RILD and further exploring the potential treatment of this disease.


Subject(s)
Carcinoma, Hepatocellular , Liver Diseases , Liver Neoplasms , Radiation Injuries , Humans , Liver Neoplasms/genetics , Liver Neoplasms/radiotherapy , Liver Neoplasms/complications , Liver Diseases/genetics , Liver Diseases/pathology , Liver/pathology , Carcinoma, Hepatocellular/genetics , Carcinoma, Hepatocellular/radiotherapy , Radiation Injuries/genetics , Radiation Injuries/complications , DNA Damage
SELECTION OF CITATIONS
SEARCH DETAIL
...